Kornimate/medical-research-clean huggingface dataset:
an electromyography study comparing the impact of using rmes on muscle activity among growing orthodontic patients

Conditions: Malocclusion

Summary: compare the impact of using rapid maxillary expanders on masticatory muscle activities (masseter and anterior temporalis muscles) among different posterior cross-bite patient (unilateral, bilateral) as well as compare the cross-bite side and non-cross-bite sides of the same preadolescent unilateral crossbite patient before the expansion and after one month of the completion treatment period using surface electromyography device.

compare the impact of using rapid maxillary expanders on masticatory muscle activities (masseter and anterior temporalis muscles) between the cross-bite side and non-cross-bite sides of the same preadolescent orthodontic patient before the expansion and after one month of the completion treatment period. two channels surface electromyography semg (bioradio), will be position to record the activity of anterior temporal (at) and masseter (mm) muscles in three different statuses: * rest → patients will instruct to not bite on his/her teeth. * clench → patients will instruct to made a maximum voluntary clench on cotton rolls positioned around the first molar, for 5 sec "the cotton clench", and a maximum voluntary clench without the interposed rolls for 5 sec "the "clench". \* this procedure followed the sforza et al. protocol. * during function "mastication" → the patients will instruct to chew on a chewing gum for 20 sec (20 continuous masticatory cycles). examination frequency: the patients will be examined two times as follow: test 1: immediately before rapid maxillary expanders cementation, test 2: 5 months later (1 month after the retention phase). the same procedure will be done on 35 patients (control group)

Eligibility criteria:
inclusion criteria: 1. uni-lateral/ or bilateral posterior cross-bite. 2. patients with erupted permanent maxillary and mandibular first molars. 3. will be treated by rapid maxillary expanders, (the appliance planning to be worn for approximately 5 months). 4. age ranged from 9 to 12. 5. males and females. 6. not under any medications. 7. skeletal class i or class ii (based on anb angle, convexity, and wits appraisal). 8. no active caries. 9. healthy periodontal tissues. 10. subjects with no signs of tmd or condylar problems. exclusion criteria: 1. history of any functional appliance treatment. 2. oral, systemic disease or any syndromes. 3. patients under any medications. 6. patients with symptoms of temporomandibular disorders. 4. neuropathic conditions. 5. open and deep-bite.
amitriptyline and paroxetine treatment of major depression

Conditions: Unipolar Depression

Summary: activation of the hypothalamus-pituitary-adrenal system is monitored using saliva cortisol sampling during the antidepressant treatment with amitriptyline and paroxetine in moderately to severely depressed patients. additionally, serum and plasma are sampled during the 5-week study period in order to study endocrine and metabolic parameters.


Eligibility criteria:
inclusion criteria: * age: above 18 * depression according dsm-iv exclusion criteria: * bipolar disorder * substance dependency

Keywords: depression
cystic fibrosis and frailtyh what's in common?

Conditions: Frailty Syndrome; Cystic Fibrosis

Summary: the goal of this observational study is to assess the main clinical and anamnestic characteristics, and frailty syndrome in an adult cystic fibrosis population. the main question it aims to answer is the possible association of the frailty status with the main clinical, therapeutical characteristics, including the genotyping classification of cystic fibrosis patients.

participants will be assessed for the pulmonary status by spirometry (for forced expiratory volume in 1 second \[fev1 - l\]; forced expiratory volume in 1 second percent predicted \[ppfev1%\]; forced vital capacity \[fvc - l\]; forced vital capacity percent predicted \[fvc %\]; maximal mid-expiratory flow \[mmef\]); for the functional status by evaluating the activities of daily living \[adls\], and the instrumental adls \[iadls\]; and for frailty by the study of osteoporotic fractures \[sof\] index. the height and weight will be also recorded, and body mass index \[bmi\] calculated as body weight divided by height squared \[kg/m2\]. body weight will be measured in a fasting state in the morning with a mechanical balance.

Eligibility criteria:
inclusion criteria: * who met the diagnostic criteria for cf, * over 18 years old, * pathological sweat chloride levels (chloride \>60 meq/l) and two cftr mutations exclusion criteria: * who did not meet the diagnostic criteria for cf * under 18 years old * over 18 years old with normal sweat chloride levels (chloride \>60 meq/l)

Keywords: functional status frailty cystic fibrosis geriatric syndrome
use of stratafix symmetric™ to prevent incisional hernia in gastrointestinal and abdominal surgery

Conditions: C.Surgical Procedure; Disruption of Wound, Suture

Summary: comparing the use of stratafix symmetric™ sutures to standard laparotomy closure sutures.

determine whether the use of stratafix symmetric™ sutures reduces the development of ventral incisional hernia (vih) in patients undergoing complex gi surgery compared to standard laparotomy closure. determine the safety of stratafix symmetric™ sutures compared to standard laparotomy closure sutures and the impact on quality of life and level of pain.

Eligibility criteria:
inclusion criteria: 1. participant is a male or female 18 years of age or older. 2. participant is a current patient at west michigan cancer center. 3. participant is undergoing liver, pancreas or biliary or gastrointestinal surgery of a combination of the above, or other major oncological surgery. 4. participant is willing and able to provide written informed consent before surgery. exclusion criteria: 1. participant has hemodynamic instability at the conclusion of the surgery. (these subjects will be deemed disqualified). 2. participant has history of previous vih. 3. participant has a mental condition rendering the subject incapable of understanding the nature, scope and consequences of the study.
fire and ice ii trial pilot

Conditions: Persistent Atrial Fibrillation; Atrial Arrhythmia

Summary: the fire and ice ii trial (pilot) is the pilot phase of a prospective, randomized, single-blinded, multi-center, interventional post-market clinical trial, comparing efficacy and safety of isolation of the pulmonary veins (pvi) using a cryoballoon catheter or radiofrequency ablation with a thermocool® smarttouch® catheter in subjects with persistent atrial fibrillation (af).

60 patients with persistent af will be randomized 1:1 between cryoballoon ablation and radiofrequency ablation in the fire and ice ii trial pilot at 5 clinical sites in europe. the data collected within the pilot phase will be reviewed and a decision on extending the trial with an extended number of patients and sites as main phase will be taken.

Eligibility criteria:
key inclusion criteria * documentation of symptomatic persistent af (following the european society of cardiology (esc) guideline 2016) defined as: persistent af - af that lasts longer than 7 days, including episodes that are terminated by cardioversion, either with drugs or by direct current cardioversion, after 7 days or more * date of first diagnosis of persistent af within the last 12 months preceding the date of screening * documented treatment failure or intolerance of at least one class i or class iii antiarrhythmic drug key exclusion criteria * known pre-existing hemi-diaphragmatic paralysis * prior left atrial ablation or surgical procedure (including left atrial appendage closures) * history of right atrial flutter, not ablated prior to enrollment * any cardiac surgery, myocardial infarction, percutaneous coronary intervention or coronary artery stenting which occurred within the 3 months before the eligibility assessment * unstable angina pectoris * primary pulmonary hypertension * any condition contraindicating chronic anticoagulation * any cerebral ischemic event (stroke or transient ischemic attack \[tia\]) which occurred within the 6 months before the consent date * presence of any cardiac prosthetic valves * long-standing persistent af lasting for ≥ 1 year (even when it is decided to adopt a rhythm control strategy) * new york health association (nyha) class iii or iv heart failure and/or documented left ventricular ejection fraction (lvef) \< 40% measured by acceptable cardiac testing (e.g. tte) * acute cardiac condition, including endocarditis, pericarditis or pericardial effusion * presence or likely implant of a permanent pacemaker, biventricular pacemaker or any type of implantable cardiac defibrillator (with or without biventricular pacing function) within 12 months

Keywords: ablation cryoballoon radiofrequency
acupuncture as adjuvant therapy for sleep disorders in parkinson's disease

Conditions: Parkinson Disease

Summary: sleep disorders correspond to a non-motor symptom present in dp, being represented by daytime sleepiness and maintenance insomnia. this study aims to evaluate the effects of acupuncture on sleep disorders in patients with pd assisted by pró-parkinson program at university hospital of pernambuco, brazil. its a randomized clinical trial approved by the ethics committee for research with human. it was included patients with diagnosed with idiopathic parkinson's disease, mini mental state examination (mmee) according to education, stages 1, 2 and 3 in the hoehn-yahr scale. it was used the sleep scale for parkinson's disease (pdss), a self-administered scale designed to assess nighttime sleep problems, sleep disorders and excessive daytime sleep. twenty-two subjects were allocated in two groups: experimental and control. acupuncture was applied on the acupoints f3 - bp6- vb34- ig4 - ta5 - c7 - pc6 - ig11 - vb20 - xiaochanxue once a week, eight sessions in the experimental group. the control group no suffered intervention. the paired analyzes were performed using the wilcoxon test and the independent analyzes using the mann-whitney test.


Eligibility criteria:
inclusion criteria: * diagnosed with idiopathic parkinson's disease * mini mental state examination (mmse) according to education * stages 1, 2 and 3 in the hoehn-yahr scale. exclusion criteria: * patients who have another neurological disorder associated with parkinson's disease * cardiac with pacemaker (contraindicated the use of electrotherapy).
high and low laser for subacromial impingement syndrome

Conditions: Subacromial Impingement Syndrome

Summary: shoulder pain is the third most common musculoskeletal problem after lumbar and neck diseases in clinical practice, and the most common cause of shoulder pain is subacromial impingement syndrome. the main goal of treatment is to reduce pain and to solve the mechanical problem that causes functional impairment. low-level laser treatment is an increasingly used treatment modality in the treatment of subacromial impingement syndrome as in many musculoskeletal diseases, as it promotes cell proliferation and tissue regeneration by its anti-inflammatory and photobiostimulation properties. also, high-intensity laser therapy is a treatment method that is gaining popularity in the recent years. these ultra-short impulses effect a deep action in the biological tissue (3-4 cm), with a homogeneous distribution of the light source in the irradiated soft tissue, but without excessive thermal enhancements. it reduces pain and edema with photomechanic effects in deep tissues. as far as the investigators know, there are no studies comparing these two treatment modalities in subacromial impingement syndrome yet. this study was planned to compare the efficacy of high-intensity laser therapy and low-intensity laser therapy in treatment of patients with subacromial impingement syndrome.


Eligibility criteria:
inclusion criteria: * shoulder pain for at least one month * male and female patients with age range from 25-45 years old * positive impingement test results * stage i or ii disease according to the neer classification, confirmed by mri * visual analog scale score greater than 40 mm. exclusion criteria: patients will be excluded if they have: * major trauma to the shoulder * stage iii subacromial impingement syndrome * diabetes mellitus * hypothyroidism * calcific tendinitis * adhesive capsulitis (forward flexion less than 160, horizontal abduction less than 160 * installation of cardiac pacemaker * history of a physical therapy program for the same shoulder in the last 6 months.
partial breast irradiation (pbi) for selected patients with early invasive or non-invasive breast cancer

Conditions: Ductal Breast Cancer

Summary: the purpose of this study is to determine the feasibility of partial breast irradiation in participants with early invasive or non-invasive breast cancer.

* in this study, radiotherapy is given only to a portion of the breast around the tumor bed using external radiation treatments. this approach is called "partial breast irradiation". * participants will undergo a planning session for the radiation treatments. this planning will be done by ct scan days or weeks before the start of treatment. this planning process is the same as that used to plan conventional radiation therapy treatments. * radiation therapy will begin 4-12 weeks after the last surgery of the breast in individuals not receiving chemotherapy first. for individuals receiving chemotherapy before radiation therapy, radiation therapy will start 2-6 weeks after ending chemotherapy. * we will be studying three levels of radiation doses to see which is best. the dose the participant receives will depend upon when they are enrolled on the trial. * participants will receive radiation treatment twice each day for 4 or 5 treatment days, with an overall treatment time of one week.

Eligibility criteria:
inclusion criteria: * histologically confirmed unicentric stage i invasive ductal breast cancer. histologically negative tumor margin 2mm or more from any inked edges, or no tumor in re-excision specimen or final shaved specimen. * patient may have been treated with adjuvant chemotherapy, or be on adjuvant hormonal therapy or begin hormonal therapy following xrt * 18 years of age or older * ecog performance status 0 * required laboratory data as outlined in the protocol exclusion criteria: * multicentric idc of the breast defined as discontiguous tumors separated by at least 5cm of uninvolved tissue * multifocal idc of the breast, defined as discontiguous discrete foci of invasive carcinoma, separated by uninvolved intervening tissue, but within an overall span of 5cm, or within the same breast quadrant or subareolar central region * tumor \> 2.0cm, nodal involvement, or metastatic involvement * histological evidence of: lymphovascular invasion; blood vessel invasion; extensive intraductal component; invasive lobular carcinoma and infiltrating carcinoma of mixed ductal and lobular type; dcis with microinvasion and dcis suspicious for microinvasion; infiltrating micropapillary carcinoma * known mutation carrier, including brca1 and brca2 * history of cosmetic or reconstructive breast surgery * psychiatric illness which would prevent the patient from giving informed consent * medical conditions such as uncontrolled infection, uncontrolled diabetes mellitus or connective tissue disease * participants with a "currently active" second malignancy other than non-melanoma skin cancers * patients with diffuse (\> 1 quadrant or \>5cm) suspicious microcalcifications * women who are pregnant

Keywords: non-invasive breast cancer early invasive breast cancer radiation pbi
azacytidine, bendamustine, piamprizumab in refractory/relapsed b-cell non-hodgkin's lymphoma

Conditions: Non-hodgkin Lymphoma,B Cell

Summary: this is an open label, single arm, phase i/ii for patients with r/r non-hodgkin's lymphoma . the purpose is to evaluate the safety and efficacy of the combination with azacytidine, bendamustine and piamprizumab


Eligibility criteria:
inclusion criteria: 1. age ≥18 and ≤80 years 2. performance status (ecog) between 0 and 3. 3. histologically confirmed b-cell non-hodgkin lymphoma (nhl), including the following types defined by who 2016. 4. refractory disease or relapsed after treatment with ≥2 lines of chemotherapy and either having failed autologous hsct or being ineligible for or not consenting to autologous hsct; or not suitable for car t treatment or resistance, progression or relapse after car t treatment; or car t pre-culturing losers can also be enrolled. 5. adequate organ function. 6. an adequate bone marrow reserve. 7. measurable or assessable disease according to the"iwg response criteria for malignant lymphoma"(cheson 2014). patients in complete remission (cr) with no evidence of disease were not eligible. 8. informed consent/assent requiring that all patients have the ability to understand and the willingness to provide written informed consent. 9. life expectancy \> 12 weeks. 10. patients with definite involvement of the gastrointestinal tract, and patients with central nervous system (cns) by petct and mri involvement were allowed to enrolled in this clinical study. exclusion criteria: 1. pregnant or lactating women. 2. uncontrolled medical disorders, active bacterial, viral infection or treponema pallidum infection and so on. 3. requirement for urgent therapy due to tumor mass effects such as respiratory obstruction or blood vessel compression. 4. current or expected need for systemic corticosteroid therapy. 5. any organ failure. 6. patients with a second tumor requiring therapy or intervention. 7. subjects considered unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation according to the investigator's judgement. 8. prior organ allograft. 9. subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.
spectralis oct repeatability and reproducibility study

Conditions: Glaucoma

Summary: this single-center, prospective, interventional clinical study is conducted to evaluate the repeatability and reproducibility of structural parameters of the optic nerve head, the peripapillary retinal nerve fiber layer, and the macula using the heidelberg spectralis oct (optical coherence tomography) device. data obtained from healthy volunteers in this study are compared to those from a previous, larger healthy volunteer study that was conducted in the united states and europe (s-2012-1), and data from glaucoma patients are compared to those from the healthy volunteers.

the study will include approximately 15 normal subjects and approximately 15 subjects who have glaucoma of varying degree. all subjects will undergo spectralis oct imaging and other study procedures in one single visit. all examinations performed on the subjects are non-significant risk procedures because the medical devices are cleared for marketing in europe and in the u.s. total study duration is anticipated to not exceed 4 weeks.

Eligibility criteria:
inclusion criteria: * subject is not an employee of the eye clinic. * age ≥18 * able and willing to undergo the test procedures, give consent, and to follow instructions. * for "normal subjects": healthy eye without prior intraocular surgery (except cataract surgery and lasik - laser-assisted refractive surgery) and without clinically significant vitreal, retinal or choroidal diseases, diabetic retinopathy, or disease of the optic nerve. * for "glaucoma subjects": early to advanced glaucoma according to existing medical charts. * refraction between +6 and -6 diopters and astigmatism ≤ 2 diopters. * when both eyes are eligible, one randomly selected eye will enter the study. exclusion criteria: • insufficient quality of spectralis oct images (this is not determined until after spectralis oct examination, and is an unusual circumstance). minimum requirements are: * retina completely included in image frame, * quality score ≥ 20 in the stored art mean images
efficacy of nitric oxide administration in attenuating ischemia/reperfusion injury during neonatal cardiopulmonary bypass

Conditions: Ischemia/Reperfusion Injury After Neonatal Cardiac Surgery; Inflammatory Reaction After Neonatal Cardiac Surgery

Summary: around 7500 neonates born yearly in the united states have complex congenital heart disease that require surgical repair in the first few days of life. the complexity of the surgical repair requires long periods of cardiopulmonary bypass (cpb) and the use of intermittent periods of low flow or complete circulatory arrest. the immature neonatal vital organs are more prone to the complications of the cardiopulmonary bypass circulation, namely ischemia/reperfusion (i/r) injury and systemic inflammatory response. inhaled nitric oxide (no) is used frequently in neonates for the treatment of pulmonary hypertension, additionally, many studies have shown that no has an anti-inflammatory effect by reducing i/r injury and endothelial dysfunction. the purpose of this pilot study is to assess the efficacy of no administration via the cpb circuit in attenuating the cpb induced i/r injury and systemic inflammatory reaction in neonates undergoing repair of complex congenital heart defects. specific goals will be to demonstrate that no use via cpb will: * decrease markers of i/r injury and systemic inflammatory response. * decrease platelet activation leading to reduced postoperative bleeding and transfusion requirements. * decrease postoperative organ dysfunction, and hence decrease operative mortality and postoperative morbidity. twelve neonates undergoing repair of complex congenital heart defects will receive no via the cpb circuit, for the duration of surgery. they will be compared to a control group of 12 similar patients. serum levels of different ischemic reperfusion injury and inflammatory markers will be measured at different time points after surgery and will be correlated with different end organ function tests and clinical course in the postoperative period. the results will be compared between the two groups to try to determine the clinical benefit of no administration through cpb circuit.


Eligibility criteria:
inclusion criteria: * neonates, age 0-30 days * full term, \> 37 weeks gestation * birth weight ≥ 2.6 kg exclusion criteria: * preoperative sepsis * preoperative renal dysfunction * preoperative intracranial hemorrhage * chromosomal abnormalities and/or genetic syndromes * prior intervention (catheter based or surgical)

Keywords: ischemia/reperfusion injury
a trial of the fatty acid amide hydrolase inhibitor palmitoylethanolamide in bipolar depression

Conditions: Bipolar Depression

Summary: the purpose of this study is to o evaluate the antidepressant efficacy of the pea in bipolar depression and the association between antidepressant response with endogenous cannabinoids and cytokine levels


Eligibility criteria:
inclusion criteria: * diagnosis of bipolar disorder according to the diagnostic and statistical manual of mental disorders (structured clinical interview), fifth edition, (dsm5), with a score of ≥16 on the 17-item ham-d * currently in use of at least one fda approved mood stabilizer with or without antidepressant * medically and neurologically healthy on the basis of medical history, physical examination exclusion criteria: * cannabis misuse according to clinical judgement * unstable medical condition or uncontrolled medical problem with known central nervous system (cns) effects * active dsm-5 substance use disorder in past three months (other than alcohol or nicotine use disorder) * acute high suicidal risk * in a manic episode * current psychotic features or cognitive impairment that would preclude understanding of the consenting process or tests/examination * pregnant or nursing women * unstable medical conditions * clinically significant abnormal laboratory tests based on complete blood count, liver and kidney function when available

Keywords: cytokine levels